CN Bio

#CN Bio #Drug discovery #Events #Life sciences #Organ-on-a-chip #R&D

Speaker line-up and scientific programme for organ-on-a-chip e-symposium 

The full scientific programme for the 2026 ‘From Insight to Decision’ e-symposium, which is taking place on 2 and 8 December, has been announced by CN Bio. The event will feature expert-led sessions offering practical, real-world guidance on organ-on-a-chip (OOC) use within existing R&D strategies.  Launched in… Read More

#News

Kidney on a chip technology
#CN Bio #Innovate UK #New approach methodologies (NAMs) #Organ-on-a-chip

CN Bio awarded Innovate UK grant to reduce animal testing

CN Bio, a provider of organ-on-a-chip (OOC) systems, has been awarded £180k ($243k) grant funding from Innovate UK.   Delivered in partnership with the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), the funding aims to support new approach methodologies (NAMs) for… Read More

#Business & Investment #News

#CN Bio #Human disease models #Organ-on-a-chip #Partnership

CN Bio signs distributor agreement in South Korea

Organ-on-a-chip (OOC) company CN Bio has agreed a strategic partnership with SCINCO, a specialist scientific instrument company based in South Korea.   The agreement is designed to amplify the CN Bio’s presence in major Asian and Pacific markets and broaden access to its predictive human organ models. … Read More

#Business & Investment #News

#CN Bio #Funding #Investment #Organ-on-a-chip

CN Bio raises $21 million in Series B investment round

Organ-on-a-chip (OOC) company CN Bio has raised a $21 million investment in the first close of its Series B fundraising round. The funding has been secured from several new investors; including $10 million from Bayland Capital, and $5.5 million from founding shareholder, CN Innovations Holdings Ltd. Read More

#Business & Investment #News

Organ-on-a-chip
#CN Bio #Inipharm #Liver disease #Organ-on-a-chip #Phase I trial #Preclinical investigations

Organ-on-a-chip data supports progression of liver disease drug

Inipharm has initiated Phase I dosing of its lead candidate, INI-822, which is a small-molecule inhibitor for HSD17B13, a gene implicated in nonalcoholic steatohepatitis (NASH). Loss-of-function variants of HSD17B13 are known to be associated with reduced incidence risk and severity of multiple liver diseases. Read More

#News

#Awards #CN Bio #Collaboration #FDA #OBN Awards #Organ-on-a-chip

CN Bio named winner with most impactful industry collaboration  

CN Bio, an organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards.   The award recognises the ongoing success of the company’s collaboration with the US Food and Drug Administration… Read More

#News

Organ on a chip
#CN Bio #Drug development #Drug screening #In vivo #Organ-on-a-chip #Organoids #SLAS

Organ-on-a-chip models in drug development

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Even with rigorous optimisation and validation, we face a 90% failure rate by the clinical phase1. Existing in vivo and in vitro models aren’t up to… Read More

#Exclusive Content

Organ-on-a-chip
#Bioavailability #CN Bio #Collaboration #FDA #In vitro #Organ-on-a-chip

FDA expands organ-on-a-chip research collaboration

The US Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ microphysiological systems (MPS) using the PhysioMimix Multi-organ System.   The system will initially be investigated for improving the preclinical estimation of human drug… Read More

#News